Advertisement

Chatting Second Messengers: PIP3 and cAMP

  • Alessandra Ghigo
  • Flora Pirozzi
  • Mingchuan Li
  • Emilio Hirsch
Chapter
Part of the Cardiac and Vascular Biology book series (Abbreviated title: Card. vasc. biol.)

Abstract

3′-5′-cyclic adenosine monophosphate (cAMP) and phosphatidylinositol 3,4,5 trisphosphate (PIP3) are pleiotropic second messengers generated in response to activation of G protein-coupled receptors (GPCRs) by a wide array of hormones and neurotransmitters. Although these small molecules engage distinct and seemingly unrelated downstream signal transducers, a growing body of evidence points to a strict cooperation of cAMP and PIP3 cascades in the control of cardiomyocyte functions. Dynamic macromolecular complexes of cAMP and PIP3 molecular switches assemble into spatially and temporally restricted microdomains. Deciphering how these compartmentalized complexes form and affect the interactions between the two signaling systems is of crucial importance, since both pathways are severely deregulated in major cardiac diseases, such as heart failure. This chapter summarizes recently described mechanisms governing the bidirectional cross talk between cAMP and PIP3 signaling pathways in the pathophysiological control of cardiovascular function. In particular, we will describe how membrane-located PIP3 affects both initiation and termination of cAMP signaling as well as the negative feedback loop whereby the small and diffusible intracellular messenger, cAMP, influences PIP3 production.

Keywords

Cyclic AMP Protein kinase A Phosphatidylinositol 3,4,5 trisphosphate Protein kinase B β-Adrenergic receptor Phosphodiesterase Heart failure 

Notes

Compliance with Ethical Standards

Conflict of Interest Statement

Emilio Hirsch is cofounder of Kither Biotech, a company involved in the development of PI3K inhibitors. The other authors declare no conflict of interest.

References

  1. Ahmad F, Lindh R, Tang Y, Weston M, Degerman E, Manganiello VC (2007) Insulin-induced formation of macromolecular complexes involved in activation of cyclic nucleotide phosphodiesterase 3B (PDE3B) and its interaction with PKB. Biochem J 404(2):257–268CrossRefPubMedPubMedCentralGoogle Scholar
  2. Dbouk HA, Vadas O, Shymanets A, Burke JE, Salamon RS, Khalil BD, Barrett MO, Waldo GL, Surve C, Hsueh C, Perisic O, Harteneck C, Shepherd PR, Harden TK, Smrcka AV, Taussig R, Bresnick AR, Nurnberg B, Williams RL, Backer JM (2012) G protein-coupled receptor-mediated activation of p110beta by Gbetagamma is required for cellular transformation and invasiveness. Sci Signal 5(253):ra89CrossRefPubMedPubMedCentralGoogle Scholar
  3. Fang R, Cui Q, Sun J, Duan X, Ma X, Wang W, Cheng B, Liu Y, Hou Y, Bai G (2015) PDK1/Akt/PDE4D axis identified as a target for asthma remedy synergistic with beta2 AR agonists by a natural agent arctigenin. Allergy 70(12):1622–1632CrossRefPubMedGoogle Scholar
  4. Feldman DS, Carnes CA, Abraham WT, Bristow MR (2005) Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med 2(9):475–483CrossRefPubMedGoogle Scholar
  5. Ghigo A, Li M (2015) Phosphoinositide 3-kinase: friend and foe in cardiovascular disease. Front Pharmacol 6:169CrossRefPubMedPubMedCentralGoogle Scholar
  6. Ghigo A, Perino A, Mehel H, Zahradnikova A Jr, Morello F, Leroy J, Nikolaev VO, Damilano F, Cimino J, De Luca E, Richter W, Westenbroek R, Catterall WA, Zhang J, Yan C, Conti M, Gomez AM, Vandecasteele G, Hirsch E, Fischmeister R (2012) Phosphoinositide 3-kinase gamma protects against catecholamine-induced ventricular arrhythmia through protein kinase A-mediated regulation of distinct phosphodiesterases. Circulation 126(17):2073–2083CrossRefPubMedPubMedCentralGoogle Scholar
  7. Han SJ, Vaccari S, Nedachi T, Andersen CB, Kovacina KS, Roth RA, Conti M (2006) Protein kinase B/Akt phosphorylation of PDE3A and its role in mammalian oocyte maturation. EMBO J 25(24):5716–5725CrossRefPubMedPubMedCentralGoogle Scholar
  8. Kitamura T, Kitamura Y, Kuroda S, Hino Y, Ando M, Kotani K, Konishi H, Matsuzaki H, Kikkawa U, Ogawa W, Kasuga M (1999) Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. Mol Cell Biol 19(9):6286–6296CrossRefPubMedPubMedCentralGoogle Scholar
  9. Laketa V, Zarbakhsh S, Traynor-Kaplan A, Macnamara A, Subramanian D, Putyrski M, Mueller R, Nadler A, Mentel M, Saez-Rodriguez J, Pepperkok R, Schultz C (2014) PIP(3) induces the recycling of receptor tyrosine kinases. Sci Signal 7(308):ra5CrossRefPubMedGoogle Scholar
  10. Madamanchi A (2007) Beta-adrenergic receptor signaling in cardiac function and heart failure. Mcgill J Med 10(2):99–104Google Scholar
  11. Mika D, Leroy J, Vandecasteele G, Fischmeister R (2012) PDEs create local domains of cAMP signaling. J Mol Cell Cardiol 52(2):323–329CrossRefPubMedGoogle Scholar
  12. Naga Prasad SV, Barak LS, Rapacciuolo A, Caron MG, Rockman HA (2001) Agonist-dependent recruitment of phosphoinositide 3-kinase to the membrane by beta-adrenergic receptor kinase 1. A role in receptor sequestration. J Biol Chem 276(22):18953–18959CrossRefPubMedGoogle Scholar
  13. Naga Prasad SV, Jayatilleke A, Madamanchi A, Rockman HA (2005) Protein kinase activity of phosphoinositide 3-kinase regulates β-adrenergic receptor endocytosis. Nat Cell Biol. 7(8):785–796Google Scholar
  14. Ndongson-Dongmo B, Heller R, Hoyer D, Brodhun M, Bauer M, Winning J, Hirsch E, Wetzker R, Schlattmann P, Bauer R (2015) Phosphoinositide 3-kinase gamma controls inflammation-induced myocardial depression via sequential cAMP and iNOS signalling. Cardiovasc Res 108(2):243–253CrossRefPubMedGoogle Scholar
  15. Omori K, Kotera J (2007) Overview of PDEs and their regulation. Circ Res 100(3):309–327CrossRefPubMedGoogle Scholar
  16. Patrucco E, Notte A, Barberis L, Selvetella G, Maffei A, Brancaccio M, Marengo S, Russo G, Azzolino O, Rybalkin SD, Silengo L, Altruda F, Wetzker R, Wymann MP, Lembo G, Hirsch E (2004) PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118(3):375–387CrossRefPubMedGoogle Scholar
  17. Perino A, Ghigo A, Ferrero E, Morello F, Santulli G, Baillie GS, Damilano F, Dunlop AJ, Pawson C, Walser R, Levi R, Altruda F, Silengo L, Langeberg LK, Neubauer G, Heymans S, Lembo G, Wymann MP, Wetzker R, Houslay MD, Iaccarino G, Scott JD, Hirsch E (2011) Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110gamma. Mol Cell 42(1):84–95CrossRefPubMedPubMedCentralGoogle Scholar
  18. Perino A, Ghigo A, Scott JD, Hirsch E (2012) Anchoring proteins as regulators of signaling pathways. Circ Res 111(4):482–492CrossRefPubMedPubMedCentralGoogle Scholar
  19. Perrino C, Naga Prasad SV, Patel M, Wolf MJ, Rockman HA (2005) Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression. J Am Coll Cardiol 45(11):1862–1870CrossRefPubMedGoogle Scholar
  20. Perrino C, Schroder JN, Lima B, Villamizar N, Nienaber JJ, Milano CA, Naga Prasad SV (2007) Dynamic regulation of phosphoinositide 3-kinase-gamma activity and beta-adrenergic receptor trafficking in end-stage human heart failure. Circulation 116(22):2571–2579CrossRefPubMedGoogle Scholar
  21. Reddy GR, Subramanian H, Birk A, Milde M, Nikolaev VO, Bunemann M (2015) Adenylyl cyclases 5 and 6 underlie PIP3-dependent regulation. FASEB J 29(8):3458–3471CrossRefPubMedGoogle Scholar
  22. Rockman HA, Koch WJ, Lefkowitz RJ (2002) Seven-transmembrane-spanning receptors and heart function. Nature 415(6868):206–212CrossRefPubMedGoogle Scholar
  23. Salamon RS, Backer JM (2013) Phosphatidylinositol-3,4,5-trisphosphate: tool of choice for class I PI 3-kinases. BioEssays 35(7):602–611CrossRefPubMedGoogle Scholar
  24. Stuenaes JT, Bolling A, Ingvaldsen A, Rommundstad C, Sudar E, Lin FC, Lai YC, Jensen J (2010) Beta-adrenoceptor stimulation potentiates insulin-stimulated PKB phosphorylation in rat cardiomyocytes via cAMP and PKA. Br J Pharmacol 160(1):116–129CrossRefPubMedPubMedCentralGoogle Scholar
  25. Torella D, Gasparri C, Ellison GM, Curcio A, Leone A, Vicinanza C, Galuppo V, Mendicino I, Sacco W, Aquila I, Surace FC, Luposella M, Stillo G, Agosti V, Cosentino C, Avvedimento EV, Indolfi C (2009) Differential regulation of vascular smooth muscle and endothelial cell proliferation in vitro and in vivo by cAMP/PKA-activated p85alphaPI3K. Am J Physiol Heart Circ Physiol 297(6):H2015–H2025CrossRefPubMedGoogle Scholar
  26. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11(5):329–341CrossRefPubMedGoogle Scholar
  27. Vasudevan NT, Mohan ML, Gupta MK, Hussain AK, Naga Prasad SV (2011) Inhibition of protein phosphatase 2A activity by PI3Kgamma regulates beta-adrenergic receptor function. Mol Cell 41(6):636–648CrossRefPubMedPubMedCentralGoogle Scholar
  28. Voigt P, Dorner MB, Schaefer M (2006) Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3B. J Biol Chem 281(15):9977–9986CrossRefPubMedGoogle Scholar
  29. Wilson LS, Baillie GS, Pritchard LM, Umana B, Terrin A, Zaccolo M, Houslay MD, Maurice DH (2011) A phosphodiesterase 3B-based signaling complex integrates exchange protein activated by cAMP 1 and phosphatidylinositol 3-kinase signals in human arterial endothelial cells. J Biol Chem 286(18):16285–16296CrossRefPubMedPubMedCentralGoogle Scholar
  30. Zaccolo M (2009) cAMP signal transduction in the heart: understanding spatial control for the development of novel therapeutic strategies. Br J Pharmacol 158(1):50–60CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Alessandra Ghigo
    • 1
  • Flora Pirozzi
    • 2
  • Mingchuan Li
    • 1
  • Emilio Hirsch
    • 1
  1. 1.Department of Molecular Biotechnology and Health SciencesUniversity of TorinoTorinoItaly
  2. 2.Division of Internal Medicine, Department of Translational Medical SciencesFederico II UniversityNaplesItaly

Personalised recommendations